Trilogy Capital’s Chemours CC Stock Holding History

Trilogy Capital’s Portfolio CC Stock Details CC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,550	Closed	-$179K	–	197
2018 Q3	$179K	Buy	+4,550	New	+$199K	0.02%	148

Other funds holding CC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Trilogy Capital's CC Position: Q4 2018 in Review

Trilogy Capital sold out of Chemours (CC) in Q4 2018, closing a stake of 4,550 shares — an estimated $179K sold.

Trilogy Capital first reported a position in CC in Q3 2018 and held it in 1 quarter. The position peaked at $179K in Q3 2018. 506 funds tracked by Wall St. Rank hold CC as of Q4 2018.

Trilogy Capital reported no remaining Chemours position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 4,550 Chemours shares in Q4 2018, an estimated $179K.
Trilogy Capital first reported a position in Chemours in Q3 2018 and held it in 1 quarter.
Trilogy Capital's Chemours position peaked at $179K in Q3 2018.
506 funds tracked by Wall St. Rank held Chemours as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.